Loading
Ipatasertib is an experimental small-molecule drug from Hoffmann-La Roche in phase 3 trials for HR-positive / HER2-negative breast cancer and ovarian cancer, aimed at AKT.
Ipatasertib (GDC-0068, RO5532961, RG7440) is a small-molecule drug developed by Hoffmann-La Roche. Its target is AKT (the sponsor names AKT). ClinicalTrials.gov describes the intervention as: For participants 12-17 years of age, ipatasertib will be administered at the starting dose of 200 mg for participants \< 35 kg, 300 mg for participants ≥35 and \< 45 kg, 400 mg for those ≥ 45 kg orally QD, beginning of Cycle 1, on Days 1-21. It is the investigational product in 5 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT05862285 (A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study), in HR-positive / HER2-negative breast cancer and ovarian cancer. The largest, NCT03424005, plans to enrol 1132 participants with primary completion expected 2030-09-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Small-molecule drug directed at AKT, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated. Connects to AKT.
1.Ipatasertib slips into a pocket on AKT.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
It is the prospective test of the PI3K and androgen receptor feedback hypothesis in men, and it shows both halves of the answer: the biomarker-selected population benefits, and the benefit is small enough that the toxicity has to be weighed honestly.
LOTUS and PAKT together made the PI3K/AKT/PTEN-altered subgroup the target population for AKT inhibitors in TNBC; the phase 3 IPATunity130 later failed to confirm it, which is why no AKT inhibitor is approved here.
Query for this drug: (TITLE:"Ipatasertib" OR ABSTRACT:"Ipatasertib" OR TITLE:"GDC-0068" OR ABSTRACT:"GDC-0068" OR TITLE:"RO5532961" OR ABSTRACT:"RO5532961" OR TITLE:"RG7440" OR ABSTRACT:"RG7440") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Ipatasertib, not a curated reading list.
Shares LOTUS, IPATunity130, BARBICAN, Metastatic triple-negative breast cancer and the tag pipeline.
Shares Ovarian cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Early triple-negative breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares HR-positive metastatic breast cancer after CDK4/6 inhibitors, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares HR-positive metastatic breast cancer after CDK4/6 inhibitors, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares HR-positive metastatic breast cancer after CDK4/6 inhibitors, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Ovarian cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag pipeline.